Skip to main content
Quest Diagnostics

Assessing the Clinical Utility of a Breakpoint Analysis Method in Identification of Structural Variants in Targeted Sequencing Genetic Tests

ESHG 2024

European Society for Human Genetics

Berlin, Germany, June 1-4, 2024

Poster presentation: Assessing the Clinical Utility of a Breakpoint Analysis Method in Identification of Structural Variants in Targeted Sequencing Genetic Tests

Authors: Andreevskaya M, Muona M, Koskinen L*, Pietilä T, Djupsjöbacka J, Kytölä V, Kämpjärvi K, Myllykangas S, Salmenperä P, Koskenvuo J, Valori M

Specialty: Genetics

Disclaimer: One or more of the authors of this abstract were employed at the time by BluePrint Genetics, a subsidiary of Quest Diagnostics.

Related content

Audio Podcast
The power of laboratory analytics
Audio Podcast
The successful convergence of clinical and operational thinking in the lab

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.